Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key HIV Studies Influencing My Practice Following AIDS 2022—Audio Redcap

July 29-August 2, 2022; Montreal, Quebec
Listen to expert insights from Chloe Orkin, MBChB, FRCP, MD, on some of the most clinically relevant new data presented at AIDS 2022, including prevention strategies, oral and long-acting therapies, cure, and COVID-19 in people with HIV.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Released: October 4, 2022

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

  • Prevention strategies
    • Data on doxycycline as postexposure prophylaxis for sexually transmitted infections in people with HIV (PWH) and those receiving pre-exposure prophylaxis (PrEP)
    • Data on 6-month PrEP dispensing and HIV self-testing in Kenya
    • Data on what women in Namibia want when it comes to PrEP
    • Outcomes for transgender women in the HPTN 083 trial comparing long-acting (LA) cabotegravir (CAB) vs daily oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) as PrEP in transgender women and men who have sex with men
    • Data on LA CAB for PrEP in women from an additional 1-year unblinded period of HPTN 084
  • Oral therapies
    • ALLIANCE study of bictegravir/FTC/tenofovir alafenamide vs dolutegravir + FTC/TDF for HIV/hepatitis B virus coinfection
    • SIMPL’HIV Wk 144 outcomes comparing switch to dolutegravir + FTC vs continued 3-drug antiretroviral therapy (ART) in patients with virologic suppression
  • LA therapies
    • CARLOS study of patient and healthcare professional perspectives on switching from daily oral ART to LA CAB + rilpivirine
    • CARISEL phase IIIb implementation study of CAB + rilpivirine for ART in Europe
    • Lenacapavir resistance and injection-site reaction data from the CALIBRATE and CAPELLA studies
  • Cure
    • City of Hope case of patient with prolonged HIV-1 remission without ART after allogeneic stem cell transplant
  • COVID-19 in PWH
    • WHO data on in-hospital mortality from COVID-19 among PWH

Information on this Educational Activity


Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead Sciences, Janssen, MSD, ViiV Healthcare; researcher: AstraZeneca, Gilead Sciences, Janssen, MSD, ViiV Healthcare.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Related Content

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this podcast from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: February 1, 2023

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 20, 2023 Expired: January 19, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings